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Breast cancer progression toward metastatic disease is linked to re-activation of epithelial–
mesenchymal transition (EMT), a latent developmental process. Breast cancer cells under-
going EMT lose epithelial characteristics and gain the capacity to invade the surrounding
tissue and migrate away from the primary tumor. However, less is known about the possi-
ble role of EMT in providing cancer cells with properties that allow them to traffic to distant
sites. Given the fact that pro-metastatic cancer cells share a unique capacity with immune
cells to traffic in-and-out of blood and lymphatic vessels we hypothesized that tumor cells
undergoing EMT may acquire properties of immune cells. To study this, we performed
gene-profiling analysis of mouse mammary EpRas tumor cells that had been allowed to
adopt an EMT program after long-term treatment with TGF-β1 for 2 weeks. As expected,
EMT cells acquired traits of mesenchymal cell differentiation and migration. However, in
addition, we found another cluster of induced genes, which was specifically enriched in
monocyte-derived macrophages, mast cells, and myeloid dendritic cells, but less in other
types of immune cells. Further studies revealed that this monocyte/macrophage gene clus-
ter was enriched in human breast cancer cell lines displaying an EMT or a Basal B profile,
and in human breast tumors with EMT and undifferentiated (ER−/PR−) characteristics.The
results identify an EMT-induced monocyte/macrophage gene cluster, which may play a role
in breast cancer cell dissemination and metastasis.
Keywords: epithelial–mesenchymal transition, breast cancer, immune cells, monocytes, macrophages, gene
expression profiling, properties
INTRODUCTION
Metastasis is a complex multistep process whereby pro-metastatic
cancer cells manage to break through cellular and molecular bar-
riers and adapt to foreign microenvironments as they traffic to,
and colonize distant organs (1, 2). The journey starts at primary
tumor sites, where cancer cells invading through the basement
membrane and into the surrounding tissue may migrate away
from the primary tumor. For further trafficking and completion
of the metastatic process, they need to intravasate into blood and
lymphatic vessels, and stay alive in the circulation. Finally, they
need to extravasate from vessels and propagate at distant sites.
Based on both clinical observations and experimental data, it
appears that only a minor fraction of cancer cells actually dis-
play all these pro-metastatic capabilities (1–4). Yet, it is not clear
what these properties are, or how they are induced and maintained
throughout the metastatic journey.
Epithelial–mesenchymal transition is considered to play an
important role in the initial parts of the metastatic cascade –
providing cancer cells with invasive, migratory, and cancer stem
cell properties (5–7). Epithelial–mesenchymal transition (EMT)
is a plastic process, and migratory cancer cells may cycle between
epithelial and mesenchymal states (8, 9). Yet, less is known about
the role of EMT in regulating trafficking of tumor cells in-and-out
of blood and lymphatic vessels. The term “mesenchymal” is a
rather unspecific definition. Although it may adequately describe
the elongated, fibroblast-like morphology, and the invasive and
migratory properties of EMT cells, it may not be sufficient to fully
describe the properties of pro-metastatic EMT cells capable of
disseminating through vessels and tissues. Clearly, fibroblasts and
other type of normal mesenchymal cells do not migrate similar to
metastatic cancer cells. Instead, the only cells that actually do traffic
in our bodies similar to metastatic cancer cells are immune cells. In
fact, immune cells are highly specialized in migrating through ves-
sels and various tissue compartments as they migrate to different
sites during inflammation.
Recently, it has been reported that circulating tumor cells
(CTCs) in breast cancer patients may display epithelial, or mes-
enchymal/EMT properties, or a combination of both (10). Inter-
estingly, the presence of CTCs with EMT properties was associated
with worse prognosis. This suggests that migratory tumor cells that
are capable of maintaining their EMT phenotype, not only within
the primary tumor and its surroundings, but also as they migrate
further and eventually reach the circulation, may represent a pool
of pro-metastatic tumor cells.
We hypothesized that breast cancer cells not only being able
to undergo EMT, but to sustain an EMT program, might develop
properties that may be used at later steps of the metastatic process.
In particular, we were interested to determine whether such EMT
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cells would acquire immune cell properties, which might be used
for trafficking through the vasculature and dissemination to dis-
tant sites. To begin to address this, we performed gene expression
profiling of mammary tumor EpRas cells that had been allowed
to adopt an EMT program after long-term treatment with trans-
forming growth factor beta 1 (TGF-β1) for 2 weeks. TGF-β1 is
an inflammatory cytokine and a potent inducer of EMT (11). We
found that long-term EMT cells indeed display properties of mes-
enchymal cells (fibroblasts). However, in addition, we identified
a cluster of EMT-induced genes enriched in monocyte-derived
immune cells including macrophages, mast cells, and myeloid den-
dritic cells (DCs). This cluster was enriched in human breast cancer
cell lines classified as Basal B cells, and in human breast tumors
negative for estrogen and progesterone receptors. It will be of inter-
est for further studies to determine the role of genes within this
cluster in breast cancer metastasis.
MATERIALS AND METHODS
CELL CULTURE
Mouse mammary EpRas tumor cells were a kind gift from the lab-
oratory of H. Beug (Wien, Austria) and were generated through
stable overexpression of the Ha-Ras oncogene in mouse mam-
mary EpH4 epithelial cells (12). EpRas cells were cultured as
adherent epithelial cells in DMEM/F12 medium supplemented
with 10% fetal calf serum (FCS), 1% penicillin/streptomycin, and
1% l-glutamine. Cells were treated with 5 ng/ml recombinant
human TGF-β1 (Peprotech Nordic, Stockholm, Sweden) for 48 h,
or 2 ng/ml for 7 or 14 days (long-term). During treatment for 7 and
14 days cells were split every 3 days and new TGF-β1 was added in
new DMEM/F12 medium supplemented with 10% FCS, 1% peni-
cillin/streptomycin, and 1% l-glutamine. Cells were culture in a
humidified incubator (37°C, 5% CO2). For gene expression analy-
sis by microarray and q-PCR, 5× 105 cells of treated and non-
treated cells were seeded in six-well plates 48 h prior to cells lysis.
IMMUNOFLUORESCENCE ANALYSIS
Cells grown on coverslips were fixed in absolute ethanol for 20 min.
Samples were blocked in incubation buffer (5% normal goat serum
and 0.1% BSA in PBS) for 1 h at room temperature. Primary anti-
body was diluted in 0.1% BSA/PBS and incubated 1 h at room
temperature. The following primary antibodies and dilutions were
used: mouse anti-E-cadherin (1:1000; clone 36, BD Biosciences,
Stockholm, Sweden) and vimentin (1:1000; clone VI-10, Abcam,
Cambridge, UK). Cells were washed five times in PBS/BSA and
further incubated with secondary antibodies (1:1000 dilution)
for 30 min and mounted in vectashield mounting media supple-
mented with DAPI (Vector Laboratories Ltd, Peterborough, UK).
Immunoflouresent staining was assessed using a Nikon Eclipse
microscope equipped for immunofluorescence.
GENE EXPRESSION ANALYSIS (Q-PCR)
Total RNA was extracted using an RNeasy mini kit (Qiagen,
Valencia, CA, USA) according to manufacturer’s instructions. An
amount of 2µg of total RNA per sample was used for first-
strand cDNA synthesis using the iScript cDNA synthesis kit
(BioRad, Solna, Sweden). For q-PCR analysis, 5 ng of cDNA
was used for PCR amplification by KAPA SYBR fast q-PCR
kit (Kapa Biosystems, Wilmington, MA, USA) with validated
QuantiTect primers (Qiagen). The following genes were ana-
lyzed: Cdh1 (primer: QT00121163), Ocln (primer: QT00111055),
Cdh5 (primer: QT00110467), Snai1 (primer: QT00240940),
Snai2 (primer: QT00098273), Zeb1 (primer: QT00105385), Zeb2
(primer: QT00148995), and Twist1 (primer: QT00097223). The
PCR was carried out as follows: 3 min at 95°C followed by 35
cycles of 3 s at 95°C, 20 s at 55°C, and 2 s extension step at 72°C in
RotorGene RG-3000A PCR system.
WESTERN BLOT
Cells were lysed in RIPA buffer [50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS supplemented with protease inhibitors (Complete, Roche,
Basel, Switzerland)]. Further, samples were boiled in Laemmli
sample buffer (BioRad), separated by SDS–PAGE under reducing
conditions, and transferred to a nitrocellulose membrane using
the iBlot (Invitrogen, Carlsbad, CA, USA) dry transfer. The mem-
brane was blocked using Blocking reagent (Roche) for 1 h and then
incubated with primary antibodies over night at 4°C. Following
antibodies were used: rabbit-α-LSP1 (1:500, HPA019693, Atlas,
Stockholm), chicken-αCotl1 (1:500) (13), rabbit-α-Dock8 (1:500,
HPA003218, Atlas, Stockholm), and rabbit-α-Calnexin (1:1000)
(14). Further secondary antibodies, α-mouse and α-rabbit Horse-
radish peroxidase IgG (1:8000, #7074, Cell Signaling Technology,
Danvers, MA, USA), were incubated for 1 h at room tempera-
ture. All antibodies were diluted in blocking reagent (Roche).
Immunoreactive bands were visualized by chemiluminescence
(Roche) and developed using a LAS1000 system (Fuji Photo
Film Co.).
MICROARRAY ANALYSIS
Microarray analysis was performed at the core facility for Bioinfor-
matics and Expression Analysis (BEA) at the Karolinska Institutet.
Total RNA was prepared from triplicate samples of EpRas cells that
were either left untreated, or treated for long-term (14 days) with
2 ng/ml of TGFβ1 (Peprotech), and purified using RNeasy Mini
Kit (Qiagen), supplemented with RNase-Free DNase (Qiagen).
One hundred fifty nanogram of total RNA per sample was used to
synthesize cDNA using a cDNA synthesis kit (Ambion/Life Tech-
nologies, Stockholm, Sweden). A GeneChip Sense Target Labeling
kit (Affymetrix) was used to fragment and biotin label single
stranded cDNA, which was probed on a MoGene-1_1-st-v1 array
(Affymetrix) using an Affymterix Gene Titan instrument. Data
were analyzed using the Robust Multi-array Average (RMA) algo-
rithm. Gene expression data presented in this manuscript have
been deposited to the Gene Expression Omnibus (GEO) database
(Accession number: GSE59922).
CLUSTER ANALYSIS OF GENES REGULATED DURING LONG-TERM
INDUCED EMT
Cluster analysis of genes upregulated or downregulated more
than 1.5-fold was performed using the Database for Annotation,
Visualization, and Integrated Discovery (DAVID)1, which is based
on functional annotation of genes. Clusters with a P ≤ 0.05 were
considered as significantly enriched.
1http://david.abcc.ncifcrf.gov/
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META-ANALYSIS OF THE EXPRESSION OF LONG-TERM INDUCED EMT
GENES IN IMMUNE CELLS
All 515 genes significantly upregulated by >1.5-fold in long-
term EMT cells were analyzed for their degree of expression in
fibroblasts (NIH3T3 and mouse embryonic fibroblasts) and dif-
ferent types of immune cells using the BioGPS database2. Gene
expression was defined as “enriched” if the level in a certain cell
type was higher than the average level for all 96 human tissues
and cell lines included in the database. The following type of
immune cells were included: Dendritic plasmacytoid (B220+),
DCs lymphoid (CD8α+), DCs myeloid (CD8α−), Macrophage
bone marrow, Macrophage (peri LPS thio 0 h), Mast cells, Gran-
ulocytes (Mac1+/Gr1+), NK cells, T cells FoxP3+, B cells GL7
positive Alum, B cells GL7 positive KLH, B cells (GL7 negative
KLH), B cells (GL7 negative Alum), B cells marginal zone, T cells
(CD4+), and T cells (CD8+).
One hundred twenty-three genes were found to be enriched in
myeloid DCs, Macrophages, Mast cells, and Granulocytes, but not
in fibroblasts, and were clustered into a monocyte/macrophage
group, which was further analyzed.
META-ANALYSIS OF THE EXPRESSION OF LONG-TERM INDUCED EMT
GENES IN HUMAN BREAST CANCER CELL LINES
The 123 genes induced in long-term EMT cells and enriched in the
monocyte/macrophage gene cluster were analyzed for their expres-
sion in datasets from 51 human breast cancer cell lines available
from the European Bioinformatics Institute at the European Mol-
ecular Biology Laboratory (EMBL-EBI)3. The E-GEOD-41313 51
database, which contains microarray profiles (Affymetrix HT HG-
U133+ PM Array Plate) of 51 human breast cancer cell lines,
was used.
First, all tumor cell lines in the database were analyzed for
the expression of EMT markers. The ratio between the average
expression values of the mesenchymal markers TWIST, SNAIL1,
and VIM, and the epithelial markers OCLN, CLDN3, and CDH1,
was calculated for the 51 cell lines. Cell lines with a mesenchy-
mal/epithelial ratio higher than 1.1 were defined as tumors dis-
playing EMT characteristics. The average expression of the mono-
cyte/macrophage gene cluster was compared between the EMT
and non-EMT groups of cell lines. The expression value for each
gene was normalized to the average expression of that gene in
all samples. Statistical differences with P ≤ 0.05 were defined as
significant.
Second, 38 of the human breast cancer cell lines were grouped
into Luminal, Basal A, and Basal B cells, according to a pre-
vious classification (15). The average expression of the mono-
cyte/macrophage gene cluster was compared between the different
classes of cell lines and P ≤ 0.05 was considered as a significant
difference.
META-ANALYSIS OF THE EXPRESSION OF LONG-TERM INDUCED EMT
GENES IN HUMAN BREAST TUMORS
Genes within the monocyte/macrophage gene cluster were ana-
lyzed for their expression in a database (E-GEOD-36771) of
2http://biogps.org/
3http://www.ebi.ac.uk/
microarray datasets (Affymetrix GeneChip Human Genome U133
Plus 2.0) from 107 human breast tumors (EMBL-EBI).
First, the average expression of genes in the mono-
cyte/macrophage cluster was calculated for each tumor sample.
Second, the average values were compared to ER/PR status, and the
expression of EMT markers (using the same strategy as described
for the tumor cell lines). P ≤ 0.05 was considered as a significant
difference.
STATISTICAL ANALYSIS
Data represent means± SEM with three independent experiments
in triplicate. Statistical analyses were determined by using Stu-
dent’s t test. P < 0.05 was considered as significant difference
between the groups. In experiments with multiple groups, Bon-
ferroni’s test for multiple comparisons was used, and P≤ 0.05 was
considered as significant.
RESULTS
LONG-TERM INDUCTION OF EMT
Mouse mammary EpRas tumor cells were treated with 5 ng/ml of
TGF-β1 for 48 h, or with 2 ng/ml for 7 days or 14 days (long-term)
to study the effect on the commonly used EMT markers E-cadherin
and vimentin. Immunoblotting analysis showed slight reduction
in E-cadherin levels and increased expression of vimentin in EpRas
cells that had been treated with TGF-β1 for 48 h, compared to non-
treated cells (Figure 1A). After 7 and 14 days of TGF-β1 treatment,
FIGURE 1 | Characteristics of long-term EMT cells. (A,B) Western blot
analysis showing more prominent changes in E-cadherin and vimentin
expression in EpRas tumor cells after 14 days (B) compared to 48 h (A) of
TGF-β1 exposure. Calnexin was used as a internal loading control.
(C) Brightfield and immunofluorescence images showing that EpRas cells
exposed to TGF-β1 for 14 days acquire characteristic features of EMT
including an elongated, fibroblast-like morphology (left panels), loss of
E-cadherin at cell–cell junctions (middle panels), and cytoplasmic staining of
vimentin (right panels). Scale bars: 20µm (left panels); 5µm (middle and
right panels).
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changes in E-cadherin and vimentin levels were more pronounced
(Figure 1B; Figure S1 in Supplementary Material). After 14 days,
E-cadherin was no longer detected in TGF-β1 treated cells. Micro-
scopic analysis demonstrated that these cells had adopted an elon-
gated, spindle-like shaped morphology, a characteristic feature
of EMT (Figure 1C). Furthermore, immunofluorescence stain-
ing showed that E-cadherin was absent at cell–cell junctions while
vimentin was localized in the cytoplasm in these long-term treated
cells. Together, these results indicated that EpRas cells that had
been treated with TGF-β1 for 48 h were in the induction phase of
EMT and thus, displayed both epithelial and mesenchymal proper-
ties. In contrast, EpRas cells that had been treated with TGF-β1 for
14 days had lost epithelial features indicating that they had been
reprogramed into mesenchymal-like cells. Based on these results,
we decided to focus on profiling long-term EMT cells to identify
their properties, based on gene expression.
LONG-TERM EMT CELLS DISPLAY MESENCHYMAL PROPERTIES
Microarray-based gene expression profiling of triplicate samples
revealed that 515 genes were significantly upregulated, and 463
genes downregulated by more than 1.5-fold in long-term EMT
cells compared to control cells (Figure 2A). The whole array set
can be accessed at GEO database (Accession number: GSE59922).
The 100 most upregulated and downregulated genes are displayed
in Tables S1 and S2 in Supplementary Material). As expected,
epithelial genes known to be inactivated during EMT in breast
cancer cells, such as Cdh1 (E-cadherin), Ocln (Occludin), Epcam,
Cldn7 (Claudin 7), Id1, Krt7, Esr1, Cav2, Dsp, Gata3, and Cadm1
were among the downregulated genes. Reciprocally, known EMT-
related genes, such as Tnc,Mmp9, Jag1, Itgb3,Cdh5, Sema7a,Ctsw,
and Itg5 were among the genes significantly upregulated in long-
term EMT cells. Changes in the expression of several of these genes
were validated by q-PCR (Figure S2A in Supplementary Material).
Interestingly, Zeb1 and Zeb2 were the only known EMT-
inducing transcription factors that were upregulated in long-term
EMT cells. In contrast, none of the master regulators of EMT –
Snai1, Snai2, and Twist1, nor the EMT promoting factors Tcf3/4,
Lef1, Foxc2, and Ets1 were upregulated. In addition, the expression
of known epigenetic regulators of EMT including Hdac factors
(Hdac1-6) and Mcm factors (Mcm 2-7 ) was unchanged in long-
term EMT cells. Expression of Snai1, Snai2, and Twist1 instead
appeared to peak at earlier time points as assessed by q-PCR analy-
sis of EpRas cells treated for 48 h or 7 days with TGF-β1 (Figure
S2B in Supplementary Material).
Cluster analysis showed that the induced genes were associated
with mesenchymal cell differentiation, cell migration, and motility
FIGURE 2 | Gene expression profiling of long-term EMT cells. (A) Heat map showing genes significantly (P ≤0.05) upregulated (515 genes, upper part) or
downregulated (463 genes, lower part) by >1.5-fold in long-term EMT vs. control EpRas cells. (B) Results from cluster analysis of genes significantly
upregulated or downregulated in long-term EMT cells.
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(Figure 2B; Table S3 in Supplementary Material). In addition,
genes encoding proteins involved in non-epithelial cell–cell adhe-
sion including various integrins (Itga2, Itga5, Itga7, and Itgb3) and
cadherins (Cdh5, Cdh10, and Cdh17 ), as well as other cell adhe-
sion molecules, such as Ncam1, Alcam, and Mcam, were induced.
As expected, downregulated genes were linked to epithelial differ-
entiation or development, and cell adhesion. Some downregulated
genes were also associated with positive regulation of cell death.
IDENTIFICATION OF A MONOCYTE/MACROPHAGE GENE CLUSTER
INDUCED IN LONG-TERM EMT CELLS
We used the BioGPS database to compare the expression of the
515 induced EMT genes in both mesenchymal cells (NIH3T3 and
Mouse Embryonic Fibroblasts), and different types of immune
cells. As expected, a large cluster of genes was enriched in fibrob-
lasts (Figure 3). In addition, we found another cluster of 123 genes
that was significantly enriched in monocyte-derived macrophages,
mast cells, and DCs of a myeloid type, but not in B cells, T cells,
other type of DCs, or granulocytes.
The largest pool of genes in this monocyte/macrophage cluster
encodes plasma membrane proteins. Some of these, such as Cd53,
Gab2, Glipr1, Laptm5, Lsp1, and Rap2a were enriched in differ-
ent types of monocyte-derived cells (macrophages, mast cells, and
myeloid DCs) (Table 1). Others, such as Cnnm4, Kctd13, Fyn,
Dag1a, and Sema6d were more restrictively enriched in some of
the cell types. A similar type of variation in enrichment between
different genes and different type of immune cells was seen for
the second and third largest sets of genes, which encode nuclear
and cytosolic proteins, respectively. Western blot analysis was
performed to validate changes in gene expression for one gene
from each of the groups encoding plasma membrane (Lsp1),
cytosol (Dock8), and cytoskeletal (Cotl1) proteins (Figure S3 in
Supplementary Material).
MONOCYTE/MACROPHAGE GENE CLUSTER IS LINKED TO EMT IN
HUMAN BREAST CANCER
Next, we performed studies to determine whether the mono-
cyte/macrophage gene cluster, which we found was induced in
long-term EMT cells, could be linked to EMT in human breast
cancer cells and tumors. For this, we took advantage of published
microarray-based datasets available through the EMBL-EBI data-
base. First, we compared the expression levels of genes within
the monocyte/macrophage cluster in 51 human breast cancer cell
lines. We found that the average expression of the genes was sig-
nificantly (P ≤ 0.001) higher in cell lines that displayed features
of EMT, compared to non-EMT cell lines (Figure 4A). In addi-
tion, we compared the expression of the gene cluster in breast
cancer cell lines previously classified as Basal B, Basal A, or Lumi-
nal cells (15). In these earlier studies, it was found while luminal
breast cancer cells appeared most differentiated, Basal cells were
less differentiated. In particular, Basal B cells were found to dis-
play EMT features. We found that the monocyte/macrophage gene
cluster was significantly more expressed in cells classified in Basal B
compared to Luminal or Basal A cell lines (P ≤ 0.01) (Figure 4B).
Finally, we also compared the expression of the EMT-
induced monocyte/macrophage gene cluster in samples of human
breast cancer. The gene cluster was significantly more expressed
(P ≤ 0.01) in estrogen receptor and progesterone receptor negative
FIGURE 3 | Identification of a monocyte/macrophage cluster in
long-term EMT cells. Radar chart showing the number of genes
upregulated in long-term EMT cells and enriched in mesenchymal cells
[NIH3T3 and mouse embryonic fibroblasts (MEF)] or various types of
immune cells. The highest number of genes was found in MEFs (202)
followed by macrophages (bone marrow: 124, peripheral: 121), mast cells
(124), NIH3T3 cells (108), and dendritic cells myeloid (106). Other immune
cells had lower numbers that pended between 63 and 89. Thus, in addition
to mesenchymal properties, properties of monocyte-derived cells were
enriched in long-term EMT cells.
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Table 1 | List of genes induced by >1.5-fold in long-term EpRas EMT cells and enriched in human myeloid cells.
FIGURE 4 |The EMT-induced monocyte/macrophage cluster is linked to
EMT in human breast cancer. (A,B) Bar graphs showing that the average
expression level of the EMT-induced monocyte/macrophage cluster was
increased in human breast cancer cell lines displaying EMT vs. non-EMT
properties, and in basal B cells compared to luminal and basal A cells.
(C,D) Bar graphs showing that the average expression level of the
EMT-induced monocyte/macrophage cluster was increased in human breast
cancer samples negative for estrogen and progesterone receptors (ER−/PR−)
compared to ER+/PR+ tumors, and in tumors displaying EMT vs. non-EMT
properties.
tumors (ER−/PR−), which are classified as the most aggres-
sive and least differentiated breast tumors (16), compared to
ER+/PR+ tumors (Figure 4C), as well as in EMT tumors
compared to non-EMT tumors (P ≤ 0.01) (Figure 4D).
DISCUSSION
We tested the hypothesis that breast cancer cells that are repro-
gramed through TGF-β1-induced EMT acquire properties of
immune cells. To study this, we performed microarray-based gene
profiling of tumor cells that had been allowed to adopt an EMT
program for 14 days. In addition to the expected mesenchymal
traits that were induced in EMT cells, we identified a gene cluster,
which is enriched in monocyte-derived immune cells including
macrophages, mast cells, and myeloid DCs.
Compared to most previous studies of gene expression changes
during TGF-β1-induced EMT, which have focused on the first
24–72 h (17, 18), we decided to profile tumor cells that had been
allowed to adopt an EMT phenotype for 14 days. There were sev-
eral reasons behind this approach. First, since the early phase
of TGF-β1-induced EMT is paralleled by growth inhibitory and
apoptotic responses (19), we figured that many gene expression
changes observed during this phase might not be primarily related
to the EMT response. However, with time, growth inhibitory and
apoptotic responses are released while EMT proceeds (20, 21).
Thus, we figured that profiling the late phase of EMT might give
valuable information about the transcriptional changes involved
in reprograming tumor epithelial cells into mesenchymal cells. In
comparison, reprograming of differentiated mouse and human
cells into pluripotent stem cells takes weeks, rather than days (22,
23). Second, since recent results show that tumor cells maintain-
ing an EMT profile in the circulation are the most capable ones in
forming distant metastasis (10), we speculated that cells capable of
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maintaining EMT for a sustained period might display properties
that could be important for later steps of the metastatic process
including intra- and extravasation.
As expected, cluster analysis showed that known epithelial genes
and cell adhesion molecules were the most downregulated in long-
term EMT cells. In addition, genes encoding positive regulators of
apoptosis were downregulated. We find this interesting since EMT
has been linked to survival and resistance to apoptotic stimuli in
breast cancer (24). In contrast, master regulators of EMT includ-
ing Snai1, Snai2, and Twist1 were not upregulated in long-term
EMT cells, but peaked at earlier time points. Among known EMT
inducers only Zeb2, which encodes Smad-interacting protein-1
(Sip1) (25, 26), was upregulated in long-term EMT cells. This was
somewhat surprising given the fact that these EMT inducers are
known to be rapidly induced and vital for the induction of EMT
(7, 27–33). However, other results show that after the induction of
EMT, the expression of EMT inducers, such as Snai1, declines to
almost baseline levels (34).
Together with our data, this suggests that while Snail1 and other
EMT-inducing factors are critical for the early phase of EMT, other
mechanisms come into play at later stages of EMT, as cells are
reprogramed into mesenchymal cells. Such mechanisms are likely
to play important roles in maintaining cells in an EMT state but
might also provide EMT cells with properties used at later stages
of the metastatic process. In line with this, we found that several
of the most upregulated genes in long-term EMT cells including
Tnc, Mmp9, Jag1, and Ret, are known to promote breast cancer
metastasis (35–38).
The monocyte/macrophage cluster, which we identified, con-
tains genes encoding proteins with variable intracellular localiza-
tion and molecular function. Some of these proteins have been
linked to cancer cell invasion, migration, and metastasis. For exam-
ple, Fyn encodes a member of the Src family of protein kinases
that are critical for macrophage migration (39), which promotes
invasion and migration in breast cancer (40). Enpp1 encodes
an ecto-nucleotide pyrophosphatase/phosphodiesterase (ENPP),
which is expressed in osteoclasts, and which promotes calcification
of bone (41), and facilitates breast cancer metastasis to the bone
(42). Both Fyn and Enpp1 have been linked to resistance to tamox-
ifen treatment (43, 44). Gab2, which encodes a scaffolding adapter
protein known to regulate EGF receptor signaling through ERK, is
critical for the phagocytic function of macrophages (45), and was
recently shown to promote breast cancer invasion and metastasis
(46). Glipr1, which encodes glioma pathogenesis-related protein-
1, has been linked to macrophage differentiation (47), and the
invasive potential of melanoma cells (48).
Other genes within the monocyte/macrophage cluster have
known roles in immune cells, but have been less studied in can-
cer. Cd53 encodes a tetraspanin protein, which is among the most
induced genes in macrophages exposed to lipopolysaccharide (49);
Fcer1g encodes a high affinity receptor for IgE, which is critical for
activation of mast cells and plays a key role in allergic inflamma-
tion (50). Lrrk2, which encodes leucine-rich repeat kinase 2, may
play a role in monocyte maturation and variants of this gene is
associated with an increased risk of both Parkinson’s and Crohn’s
disease (51–53). P2ry12 encodes a purinergic G protein-coupled
receptor, which promotes macrophage chemotaxis and microglial
activation (54, 55). Relt and Nrip1, which encode a member
of the tumor necrosis factor receptor superfamily, and nuclear
receptor-interacting protein-1, respectively, are both involved in
activating NF-KappaB (56, 57). Tbxas1, Dock8, and Wipf1, which
encode thromboxane A synthase 1, dedicator of cytokinesis 8, and
WAS/WASL-interacting protein family member 1, respectively,
are expressed in myeloid DCs and important for their polariza-
tion and migration (58–60). Some of the genes, such as Fcgr2b,
which encodes the cell surface protein CD32; Lsp1, which encodes
the lymphocyte-specific protein-1; and Stab1, which encodes the
scavenger receptor Stabilin-1/CLEVER-1, are known to regulate
monocyte/macrophage migration and endothelial cell interactions
(61–63).
Interestingly, some of the genes in the monocyte/macrophage
cluster have been linked to cellular stemness. In our microarray
data, genes encoding cancer stem cell markers, such as CD44
and CD133, were not significantly upregulated. However, other
genes known to regulate cellular stemness were induced. Msi1,
which encodes Musashi1, an RNA binding protein, and Wnt1,
are both master regulators of self-renewal in multiple stem cell
populations (64, 65). Sipa1 encodes a Rap1 GTPase-activating
protein essential for proliferative control of hematopoietic prog-
enitors (66). Upregulation of Cdyl2 has been found in CD133-
positive stem cells (67). Further studies are warranted to elucidate
whether any of these genes contribute with stem cell properties to
EMT cells.
In summary, our results indicate that tumor cells undergo-
ing EMT in response to TGF-β1 do not simply turn into typical
mesenchymal cells, such as fibroblasts. Rather, they acquire fea-
tures of immune cells, in particular hematopoietic cells derived
from myeloid precursors. The increased expression of genes in
the monocyte/macrophage cluster in more aggressive breast can-
cer cell lines and tumors (EMT+, Basal B+, and ER−PR−)
indicate that these genes might play roles in breast cancer metas-
tasis. Clearly, further studies are needed to analyze the role
of genes within the monocyte/macrophage cluster in provid-
ing cancer EMT cells with invasive and migratory properties.
Such studies will include loss- and gain-of-function experi-
ments to determine to the role of genes in providing EMT cells
with the capacity to perform different steps of the metastatic
process.
AUTHOR CONTRIBUTIONS
Study concept and design: Joel Johansson, Vedrana Tabor, Jonas
Fuxe; acquisition and analysis of data: Joel Johansson, Vedrana
Tabor, Anna Wikell, Jonas Fuxe; drafting of the manuscript: Joel
Johansson, Vedrana Tabor, Jonas Fuxe; and funding: Jonas Fuxe;
study supervision: Jonas Fuxe.
ACKNOWLEDGMENTS
We thank Dr. Olof Rådmark at the Department of Medical Bio-
chemistry and Biophysics at Karolinska Institutet for kindly pro-
viding us with the Cotl1/CPL antibody. Vedrana Tabor was sup-
ported by a grant from the Swedish Cancer Society. Jonas Fuxe was
supported by project grants from the Swedish Research Council,
the Swedish Cancer Society, and the Strategic Cancer (StratCan)
Programme at Karolinska Institutet.
www.frontiersin.org January 2015 | Volume 5 | Article 3 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Johansson et al. Immune cell properties of EMT cells
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at http://www.frontiersin.org/Journal/10.3389/fonc.2015.
00003/abstract
REFERENCES
1. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med (2008)
359(26):2814–23. doi:10.1056/NEJMra0805239
2. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science (2011)
331(6024):1559–64. doi:10.1126/science.1203543
3. Jahroudi N, Greenberger JS. The role of endothelial cells in tumor invasion and
metastasis. J Neurooncol (1995) 23(2):99–108. doi:10.1007/BF01053415
4. Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights
from animal models and cancer patients. Cancer Cell (2013) 23(5):573–81.
doi:10.1016/j.ccr.2013.04.017
5. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin
Invest (2009) 119(6):1420–8. doi:10.1172/JCI39104
6. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-
mesenchymal transition generates cells with properties of stem cells. Cell (2008)
133(4):704–15. doi:10.1016/j.cell.2008.03.027
7. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions
in development and disease. Cell (2009) 139(5):871–90. doi:10.1016/j.cell.2009.
11.007
8. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells.
Science (2013) 342(6159):1234850. doi:10.1126/science.1234850
9. Bednarz-Knoll N, Alix-Panabieres C, Pantel K. Plasticity of disseminating can-
cer cells in patients with epithelial malignancies. Cancer Metastasis Rev (2012)
31(3–4):673–87. doi:10.1007/s10555-012-9370-z
10. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast
tumor cells exhibit dynamic changes in epithelial and mesenchymal composi-
tion. Science (2013) 339(6119):580–4. doi:10.1126/science.1228522
11. Fuxe J, Karlsson MC. TGF-beta-induced epithelial-mesenchymal transition:
a link between cancer and inflammation. Semin Cancer Biol (2012) 22(5–
6):455–61. doi:10.1016/j.semcancer.2012.05.004
12. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-beta1 and
Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of
epithelial tumor cells. Genes Dev (1996) 10(19):2462–77. doi:10.1101/gad.10.
19.2462
13. Rakonjac M, Fischer L, Provost P, Werz O, Steinhilber D, Samuelsson B,
et al. Coactosin-like protein supports 5-lipoxygenase enzyme activity and
up-regulates leukotriene A4 production. Proc Natl Acad Sci U S A (2006)
103(35):13150–5. doi:10.1073/pnas.0605150103
14. Andersson AM, Pettersson RF. Targeting of a short peptide derived from the
cytoplasmic tail of the G1 membrane glycoprotein of Uukuniemi virus (Bun-
yaviridae) to the Golgi complex. J Virol (1998) 72(12):9585–96.
15. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of
breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell (2006) 10(6):515–27. doi:10.1016/j.ccr.2006.10.008
16. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Con-
trol (2010) 17(3):173–6.
17. Zavadil J, Bitzer M, Liang D, Yang YC, Massimi A, Kneitz S, et al. Genetic pro-
grams of epithelial cell plasticity directed by transforming growth factor-beta.
Proc Natl Acad Sci U S A (2001) 98(12):6686–91. doi:10.1073/pnas.111614398
18. Xie L, Law BK, Aakre ME, Edgerton M, Shyr Y, Bhowmick NA, et al. Transform-
ing growth factor beta-regulated gene expression in a mouse mammary gland
epithelial cell line. Breast Cancer Res (2003) 5(6):R187–98. doi:10.1186/bcr640
19. Brown KA, Aakre ME, Gorska AE, Price JO, Eltom SE, Pietenpol JA, et al.
Induction by transforming growth factor-beta1 of epithelial to mesenchymal
transition is a rare event in vitro. Breast Cancer Res (2004) 6(3):R215–31.
doi:10.1186/bcr762
20. Gal A, Sjoblom T, Fedorova L, Imreh S, Beug H, Moustakas A. Sustained TGF
beta exposure suppresses Smad and non-Smad signalling in mammary epithelial
cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene
(2008) 27(9):1218–30. doi:10.1038/sj.onc.1210741
21. Johansson J, Berg T, Kurzejamska E, Pang MF, Tabor V, Jansson M, et al. MiR-
155-mediated loss of C/EBPbeta shifts the TGF-beta response from growth inhi-
bition to epithelial-mesenchymal transition, invasion and metastasis in breast
cancer. Oncogene (2013) 32(50):5614–24. doi:10.1038/onc.2013.322
22. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors. Cell (2006)
126(4):663–76. doi:10.1016/j.cell.2006.07.024
23. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induc-
tion of pluripotent stem cells from adult human fibroblasts by defined factors.
Cell (2007) 131(5):861–72. doi:10.1016/j.cell.2007.11.019
24. Toft DJ, Cryns VL. Minireview: basal-like breast cancer: from molecular profiles
to targeted therapies. Mol Endocrinol (2011) 25(2):199–211. doi:10.1210/me.
2010-0164
25. Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H,
et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell
junctions. Nucleic Acids Res (2005) 33(20):6566–78. doi:10.1093/nar/gki965
26. Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, Noel A, et al. Reg-
ulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene
(2006) 25(36):4975–85. doi:10.1038/sj.onc.1209511
27. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The tran-
scription factor snail is a repressor of E-cadherin gene expression in epithelial
tumour cells. Nat Cell Biol (2000) 2(2):84–9. doi:10.1038/35000034
28. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, Del Barrio
MG, et al. The transcription factor snail controls epithelial-mesenchymal tran-
sitions by repressing E-cadherin expression. Nat Cell Biol (2000) 2(2):76–83.
doi:10.1038/35010506
29. Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe CJ, Yang J. Snail2 is
an essential mediator of Twist1-induced epithelial mesenchymal transition
and metastasis. Cancer Res (2011) 71(1):245–54. doi:10.1158/0008-5472.CAN-
10-2330
30. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-
cadherin in breast cancer. Cancer Res (2002) 62(6):1613–8.
31. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour pro-
gression: an alliance against the epithelial phenotype? Nat Rev Cancer (2007)
7(6):415–28. doi:10.1038/nrc2131
32. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, et al. A SNAIL1-
SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated
epithelial-mesenchymal transition. Nat Cell Biol (2009) 11(8):943–50. doi:10.
1038/ncb1905
33. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist,
a master regulator of morphogenesis, plays an essential role in tumor metastasis.
Cell (2004) 117(7):927–39. doi:10.1016/j.cell.2004.06.006
34. Shirakihara T, Saitoh M, Miyazono K. Differential regulation of epithelial and
mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transi-
tion induced by TGF-beta. Mol Biol Cell (2007) 18(9):3533–44. doi:10.1091/
mbc.E07-03-0249
35. Van Kempen LC, Coussens LM. MMP9 potentiates pulmonary metastasis for-
mation. Cancer Cell (2002) 2(4):251–2. doi:10.1016/S1535-6108(02)00157-5
36. Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes oste-
olytic bone metastasis of breast cancer by engaging notch signaling in bone cells.
Cancer Cell (2011) 19(2):192–205. doi:10.1016/j.ccr.2010.12.022
37. Gattelli A, Nalvarte I, Boulay A, Roloff TC, Schreiber M, Carragher N, et al.
Ret inhibition decreases growth and metastatic potential of estrogen receptor
positive breast cancer cells. EMBO Mol Med (2013) 5(9):1335–50. doi:10.1002/
emmm.201302625
38. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG,
et al. Breast cancer cells produce tenascin C as a metastatic niche component to
colonize the lungs. Nat Med (2011) 17(7):867–74. doi:10.1038/nm.2379
39. Baruzzi A, Iacobucci I, Soverini S, Lowell CA, Martinelli G, Berton G. c-Abl and
Src-family kinases cross-talk in regulation of myeloid cell migration. FEBS Lett
(2010) 584(1):15–21. doi:10.1016/j.febslet.2009.11.009
40. Yadav V, Denning MF. Fyn is induced by Ras/PI3K/Akt signaling and is
required for enhanced invasion/migration. Mol Carcinog (2011) 50(5):346–52.
doi:10.1002/mc.20716
41. Hajjawi MO, Macrae VE, Huesa C, Boyde A, Millan JL, Arnett TR, et al. Miner-
alisation of collagen rich soft tissues and osteocyte lacunae in Enpp1 mice. Bone
(2014) 69C:139–47. doi:10.1016/j.bone.2014.09.016
42. Lau WM, Doucet M, Stadel R, Huang D, Weber KL, Kominsky SL. Enpp1:
a potential facilitator of breast cancer bone metastasis. PLoS One (2013)
8(7):e66752. doi:10.1371/journal.pone.0066752
43. Elias D, Vever H, Laenkholm AV, Gjerstorff MF, Yde CW, Lykkesfeldt AE, et al.
Gene expression profiling identifies FYN as an important molecule in tamoxifen
Frontiers in Oncology | Cancer Epidemiology and Prevention January 2015 | Volume 5 | Article 3 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Johansson et al. Immune cell properties of EMT cells
resistance and a predictor of early recurrence in patients treated with endocrine
therapy. Oncogene (2014). doi:10.1038/onc.2014.138
44. Umar A, Kang H, Timmermans AM, Look MP, Meijer-Van Gelder ME, Den
Bakker MA, et al. Identification of a putative protein profile associated with
tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics (2009)
8(6):1278–94. doi:10.1074/mcp.M800493-MCP200
45. Gu H,Botelho RJ,Yu M,Grinstein S,Neel BG. Critical role for scaffolding adapter
Gab2 in Fc gamma R-mediated phagocytosis. J Cell Biol (2003) 161(6):1151–61.
doi:10.1083/jcb.200212158
46. Ke Y, Wu D, Princen F, Nguyen T, Pang Y, Lesperance J, et al. Role of Gab2
in mammary tumorigenesis and metastasis. Oncogene (2007) 26(34):4951–60.
doi:10.1038/sj.onc.1210315
47. Gingras MC, Margolin JF. Differential expression of multiple unexpected genes
during U937 cell and macrophage differentiation detected by suppressive sub-
tractive hybridization. Exp Hematol (2000) 28(1):65–76. doi:10.1016/S0301-
472X(99)00126-5
48. Awasthi A, Woolley AG, Lecomte FJ, Hung N, Baguley BC, Wilbanks SM, et al.
Variable expression of GLIPR1 correlates with invasive potential in melanoma
cells. Front Oncol (2013) 3:225. doi:10.3389/fonc.2013.00225
49. Kim TR, Yoon JH, Kim YC, Yook YH, Kim IG, Kim YS, et al. LPS-induced CD53
expression: a protection mechanism against oxidative and radiation stress. Mol
Cells (2004) 17(1):125–31.
50. Yu M, Tsai M, Tam SY, Jones C, Zehnder J, Galli SJ. Mast cells can promote the
development of multiple features of chronic asthma in mice. J Clin Invest (2006)
116(6):1633–41. doi:10.1172/JCI25702
51. Manolio TA. Genomewide association studies and assessment of the risk of
disease. N Engl J Med (2010) 363(2):166–76. doi:10.1056/NEJMra0905980
52. Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, et al.
Imputation of sequence variants for identification of genetic risks for Parkin-
son’s disease: a meta-analysis of genome-wide association studies. Lancet (2011)
377(9766):641–9. doi:10.1016/S0140-6736(10)62345-8
53. Thevenet J, Pescini Gobert R, Hooft Van Huijsduijnen R, Wiessner C,
Sagot YJ. Regulation of LRRK2 expression points to a functional role in human
monocyte maturation.PLoSOne (2011) 6(6):e21519. doi:10.1371/journal.pone.
0021519
54. Kronlage M, Song J, Sorokin L, Isfort K, Schwerdtle T, Leipziger J, et al. Autocrine
purinergic receptor signaling is essential for macrophage chemotaxis. Sci Signal
(2010) 3(132):ra55. doi:10.1126/scisignal.2000588
55. Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, et al. The
P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat
Neurosci (2006) 9(12):1512–9. doi:10.1038/nn1805
56. Sica GL, Zhu G, Tamada K, Liu D, Ni J, Chen L. RELT, a new member of the tumor
necrosis factor receptor superfamily, is selectively expressed in hematopoietic tis-
sues and activates transcription factor NF-kappaB. Blood (2001) 97(9):2702–7.
doi:10.1182/blood.V97.9.2702
57. Zschiedrich I, Hardeland U, Krones-Herzig A, Berriel Diaz M, Vegiopoulos
A, Muggenburg J, et al. Coactivator function of RIP140 for NFkappaB/RelA-
dependent cytokine gene expression. Blood (2008) 112(2):264–76. doi:10.1182/
blood-2007-11-121699
58. Harada Y, Tanaka Y, Terasawa M, Pieczyk M, Habiro K, Katakai T, et al. DOCK8 is
a Cdc42 activator critical for interstitial dendritic cell migration during immune
responses. Blood (2012) 119(19):4451–61. doi:10.1182/blood-2012-01-407098
59. Hata M, Takahara S, Tsuzaki H, IshiiY, Nakata K,Akagawa KS, et al. Expression of
Th2-skewed pathology mediators in monocyte-derived type 2 of dendritic cells
(DC2). Immunol Lett (2009) 126(1–2):29–36. doi:10.1016/j.imlet.2009.07.008
60. Chou HC, Anton IM, Holt MR, Curcio C, Lanzardo S, Worth A, et al. WIP regu-
lates the stability and localization of WASP to podosomes in migrating dendritic
cells. Curr Biol (2006) 16(23):2337–44. doi:10.1016/j.cub.2006.10.037
61. Devaraj S, Davis B, Simon SI, Jialal I. CRP promotes monocyte-endothelial
cell adhesion via Fcgamma receptors in human aortic endothelial cells under
static and shear flow conditions. Am J Physiol Heart Circ Physiol (2006)
291(3):H1170–6. doi:10.1152/ajpheart.00150.2006
62. Palani S, Maksimow M, Miiluniemi M, Auvinen K, Jalkanen S, Salmi M. Stabilin-
1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging mol-
ecule on human placental macrophages. Eur J Immunol (2011) 41(7):2052–63.
doi:10.1002/eji.201041376
63. Liu L, Cara DC, Kaur J, Raharjo E, Mullaly SC, Jongstra-Bilen J, et al. LSP1 is
an endothelial gatekeeper of leukocyte transendothelial migration. J Exp Med
(2005) 201(3):409–18. doi:10.1084/jem.20040830
64. Sutherland JM, Mclaughlin EA, Hime GR, Siddall NA. The Musashi family of
RNA binding proteins: master regulators of multiple stem cell populations. Adv
Exp Med Biol (2013) 786:233–45. doi:10.1007/978-94-007-6621-1_13
65. Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer
Res (2007) 13(14):4042–5. doi:10.1158/1078-0432.CCR-06-2316
66. Ishida D, Kometani K, Yang H, Kakugawa K, Masuda K, Iwai K, et al. Myelopro-
liferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient
mice. Cancer Cell (2003) 4(1):55–65. doi:10.1016/S1535-6108(03)00163-6
67. Kim ST, Sohn I, Do IG, Jang J, Kim SH, Jung IH, et al. Transcriptome analysis of
CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
Cancer Genomics Proteomics (2014) 11(5):259–66.
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 01 August 2014; accepted: 08 January 2015; published online: 26 January
2015.
Citation: Johansson J, Tabor V, Wikell A, Jalkanen S and Fuxe J (2015) TGF-β1-
induced epithelial–mesenchymal transition promotes monocyte/macrophage properties
in breast cancer cells. Front. Oncol. 5:3. doi: 10.3389/fonc.2015.00003
This article was submitted to Cancer Epidemiology and Prevention, a section of the
journal Frontiers in Oncology.
Copyright © 2015 Johansson, Tabor,Wikell, Jalkanen and Fuxe. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
www.frontiersin.org January 2015 | Volume 5 | Article 3 | 9
